PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.\', \'W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.\', \'Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.\', \'Division of Immunology, Department of Pathology.\', \'Department of Anesthesiology and Critical Care Medicine.\', \'Division of Immunology, Department of Pediatrics.\', \'Division of Transfusion Medicine, Department of Pathology.\', \'Division of Infectious Diseases, Department of Medicine, and.\', \'Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1172/jci.insight.151518e151518
?:doi
?:hasPublicationType
?:journal
  • JCI insight
is ?:pmid of
?:pmid
?:pmid
  • 34855624
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all